ClinicalTrials.Veeva
Menu

Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

V

Verastem

Status and phase

Not yet enrolling
Phase 2

Conditions

Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer

Treatments

Drug: avutometinib + defactininb combination

Study type

Interventional

Funder types

Industry

Identifiers

NCT07747506
VS-6766-206

Details and patient eligibility

About

This Open-Label Extension (OLE) study provides participants with recurrent low-grade serous ovarian cancer (LGSOC) who have completed the VS-6766-201(RAMP-201) study continued, uninterrupted access to avutometinib in combination with defactinib. The study is designed to support patients in France with access to avutometinib and defactinib who maintain ongoing clinical benefit while collecting safety and tolerability data during extended treatment. Participation is restricted to patients transferring directly from VS-6766-201(RAMP-201), ensuring continuity of care without enrollment of new patients.

Read more

Enrollment

2 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Currently active on VS-6766-201(RAMP-201) study while receiving avutometinib in combination with defactinib, have not required prior permanent discontinuation of avutometinib plus defactinib. Any active dose hold from the RAMP-201 study should be ≤ 28 days at the time of Screening for the OLE study.

  2. Investigator assessment that the participant is deriving clinical benefit from study treatment (e.g., complete response, partial response, or stable disease), as determined by the investigator.

  3. Female participants of childbearing potential must agree to use a highly effective method of contraception throughout OLE study participation and for at least 30 days after the last dose of study treatment.

    Note: Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening/Eligibility prior to the first OLE dose.

  4. Ability and willingness to provide written informed consent for participation in the study and for continued data collection.

Exclusion criteria

  1. Radiographic or clinical disease progression or discontinuation of treatment for any reason during the VS-6766-201 (RAMP-201) study or at the time of screening in this study.
  2. Participants on an active dose hold in the VS-6766-201 (RAMP-201) study may transition to this study only after the underlying issue has been clinically resolved and the investigator, in consultation with the Sponsor, confirms that continued treatment is appropriate.
  3. Receipt of new systemic anti-cancer therapy since participation in the RAMP-201 study.
  4. Participation in another interventional clinical study or receipt of other investigational therapy since participation in VS-6766-201 (RAMP-201) study.
  5. Any active or uncontrolled medical condition that, in the investigator's judgment, would pose unacceptable risk or interfere with continued treatment, including but not limited to severe cardiac, pulmonary, neurologic, dermatologic, gastrointestinal, hepatic, or active infectious disease.
  6. Any active or history of clinically significant ocular disorder that may increase the risk of MEK-inhibitor-related ocular toxicity (e.g., retinal vein occlusion, serous retinopathy, retinal detachment, or clinically significant macular pathology).
  7. Concomitant use of medications known to have clinically significant interactions with avutometinib or defactinib that cannot be safely discontinued or substituted prior to study dosing (e.g., strong CYP3A4 inducers or inhibitors, warfarin).
  8. Positive pregnancy test at Screening, breastfeeding, or unwillingness to use adequate contraception during the study.
  9. Any condition or circumstance that, in the investigator's opinion, may compromise participant safety, compliance or continued benefit from study treatment.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

2 participants in 1 patient group

Continued Treatment of Avutometinib + Defactinib
Experimental group
Description:
To provide continued treatment with avutometinib in combination with defactinib for participants with recurrent LGSOC who are deriving continued clinical benefit after completion of the VS-6766-201 (RAMP-201) study
Treatment:
Drug: avutometinib + defactininb combination

Trial contacts and locations

2

Loading...

Central trial contact

Verastem Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems